Hims & Hers Health, Inc. (NYSE:HIMS) Shares Purchased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC grew its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 239.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 98,402 shares of the company's stock after acquiring an additional 69,441 shares during the quarter. Mutual of America Capital Management LLC's holdings in Hims & Hers Health were worth $2,908,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of HIMS. Allworth Financial LP lifted its holdings in Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after purchasing an additional 334 shares during the period. Summit Investment Advisors Inc. raised its position in Hims & Hers Health by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock worth $480,000 after acquiring an additional 628 shares in the last quarter. Cim LLC raised its position in Hims & Hers Health by 1.0% in the fourth quarter. Cim LLC now owns 71,869 shares of the company's stock worth $1,738,000 after acquiring an additional 694 shares in the last quarter. Harbour Investments Inc. raised its position in Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock worth $127,000 after acquiring an additional 833 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in Hims & Hers Health by 12.9% in the first quarter. Farther Finance Advisors LLC now owns 8,122 shares of the company's stock worth $252,000 after acquiring an additional 930 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $58.40, for a total transaction of $7,482,616.80. Following the completion of the sale, the chief executive officer owned 89,311 shares of the company's stock, valued at approximately $5,215,762.40. The trade was a 58.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Melissa Baird sold 33,333 shares of Hims & Hers Health stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $25.78, for a total value of $859,324.74. Following the completion of the sale, the chief operating officer directly owned 805,083 shares in the company, valued at $20,755,039.74. This trade represents a 3.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 683,452 shares of company stock valued at $36,247,465. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Stock Performance

HIMS stock traded up $0.37 during trading on Friday, hitting $50.36. 22,036,786 shares of the company traded hands, compared to its average volume of 24,206,590. The firm has a market capitalization of $11.27 billion, a PE ratio of 72.99, a P/E/G ratio of 1.85 and a beta of 2.02. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The company has a 50-day moving average of $53.82 and a 200-day moving average of $41.92.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. During the same quarter in the prior year, the company posted $0.05 EPS. Hims & Hers Health's quarterly revenue was up 110.7% compared to the same quarter last year. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Morgan Stanley restated an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Bank of America upped their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, Truist Financial raised their price target on Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a report on Thursday. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $39.83.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.